Knight Therapeutics (TSE:GUD) Hits New 1-Year High – Time to Buy?

Shares of Knight Therapeutics Inc. (TSE:GUD) hit a new 52-week high during trading on Wednesday. The company traded as high as C$10.76 and last traded at C$10.73, with a volume of 30407 shares traded. The stock had previously closed at C$10.54.

Knight Therapeutics Price Performance

The company has a market cap of C$1.05 billion, a price-to-earnings ratio of 71.40, a price-to-earnings-growth ratio of -1,013.50 and a beta of -0.45. The company has a current ratio of 2.28, a quick ratio of 1.79 and a debt-to-equity ratio of 4.29. The company has a fifty day moving average price of C$9.87 and a two-hundred day moving average price of C$8.99.

Knight Therapeutics (TSE:GUD) last issued its earnings results on Thursday, August 6th. The company reported C($0.03) EPS for the quarter. The firm had revenue of C$143.97 million during the quarter. Knight Therapeutics had a net margin of 2.72% and a return on equity of 1.91%. As a group, equities research analysts anticipate that Knight Therapeutics Inc. will post 0.1009486 EPS for the current fiscal year.

About Knight Therapeutics

Knight Therapeutics Inc, headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc’s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc, please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.